# Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Study · id `cardio:ct-nct06153693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06153693](<https://clinicaltrials.gov/study/NCT06153693>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06153693

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1083 participants.

## Technical summary

Registry record NCT06153693. Randomized; double masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2024-12-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1083 participants (enrolled count; ClinicalTrials.gov record NCT06153693, source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)
- Started: 2023-11-22 (actual) (ClinicalTrials.gov record NCT06153693, source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)
- Primary completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT06153693, source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)
- Completion: 2025-01-24 (actual) (ClinicalTrials.gov record NCT06153693, source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)
- Countries: United States; Australia; Bulgaria; Canada; France; Germany; Italy; Netherlands; Poland; Puerto Rico; Romania; Spain; United Kingdom (ClinicalTrials.gov record NCT06153693, source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06153693-2026-05-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
- Condition: Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): lorundrostat Dose 1
- Intervention (Drug): lorundrostat Dose 2
- Lead sponsor: Mineralys Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Mineralys Therapeutics Inc. (`cardio:org-mineralys-therapeutics-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial (`cardio:pubmed-40587141`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2a0ac53faff92a8d586006a73e9d9f4e8d42b14d5072bc2b881a3103a674b107
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
